Cencora Inc
NYSE:COR
Cencora Inc
Long-Term Debt
Cencora Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Cencora Inc
NYSE:COR
|
Long-Term Debt
$3.8B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
7%
|
||
Cardinal Health Inc
NYSE:CAH
|
Long-Term Debt
$4.2B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
||
Henry Schein Inc
NASDAQ:HSIC
|
Long-Term Debt
$1.9B
|
CAGR 3-Years
39%
|
CAGR 5-Years
17%
|
CAGR 10-Years
12%
|
||
Adapthealth Corp
NASDAQ:AHCO
|
Long-Term Debt
$2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Patterson Companies Inc
NASDAQ:PDCO
|
Long-Term Debt
$325.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-8%
|
||
Mckesson Corp
NYSE:MCK
|
Long-Term Debt
$5.7B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-5%
|
Cencora Inc
Glance View
Cencora Inc., once known as AmerisourceBergen, stands as a pivotal player in the healthcare landscape, sculpting pathways for the seamless distribution of pharmaceuticals across the globe. Born from a merger of AmeriSource Health Corporation and Bergen Brunswig Corporation in 2001, the company carved its identity by building extensive networks that bind drug manufacturers, pharmacies, and healthcare providers together into a cohesive chain. This intricate web ensures that pharmaceutical products, ranging from common prescriptions to specialized drugs, reach their destinations efficiently and securely. Cencora's proficiency lies not just in logistics but in its ability to adapt and innovate within rigid regulatory frameworks, ensuring its clients navigate the complexities of compliance while focusing on patient care. In terms of profitability, Cencora thrives on its vast and exponentially growing distribution channels, earning a steady stream of revenue through service fees and percentage fees tied to the value of distributed goods. Moreover, the company's integrated service offerings, such as consulting, analytics, and supply chain management solutions, provide additional avenues of income by addressing the strategic needs of its clientele. This dual approach of logistics and consultancy allows Cencora not only to serve as a conduit for drug distribution but also as a trusted advisor in a healthcare sphere that is increasingly data-driven and efficiency-focused. Through its multi-faceted business model, Cencora secures its foundation in a volatile industry, supporting the balance of patient needs, market demands, and regulatory compliance.
See Also
What is Cencora Inc's Long-Term Debt?
Long-Term Debt
3.8B
USD
Based on the financial report for Sep 30, 2024, Cencora Inc's Long-Term Debt amounts to 3.8B USD.
What is Cencora Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
7%
Over the last year, the Long-Term Debt growth was -8%. The average annual Long-Term Debt growth rates for Cencora Inc have been -16% over the past three years , -3% over the past five years , and 7% over the past ten years .